HNSPF Quote, Financials, Valuation and Earnings

CASI Pharmaceuticals has a net margin of -- compared to Hansoh Pharmaceutical Group's net margin of -107.73%. Hansoh Pharmaceutical Group's return on equity of 18.18% beat CASI Pharmaceuticals's return on equity of -137%.

Hansoh Pharmaceutical Group has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 94.81%. Given that CASI Pharmaceuticals has higher upside potential than Hansoh Pharmaceutical Group, analysts believe CASI Pharmaceuticals is more attractive than Hansoh Pharmaceutical Group.

Hansoh Pharmaceutical Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals has a beta of 0.602, suggesting its less volatile than the S&P 500 by 39.83%.

Hansoh Pharmaceutical Group has a quarterly dividend of $0.03 per share corresponding to a yield of 2.1%. CASI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansoh Pharmaceutical Group pays 19.9% of its earnings as a dividend. CASI Pharmaceuticals pays out -- of its earnings as a dividend. Hansoh Pharmaceutical Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hansoh Pharmaceutical Group quarterly revenues are --, which are smaller than CASI Pharmaceuticals quarterly revenues of $7.8M. Hansoh Pharmaceutical Group's net income of -- is lower than CASI Pharmaceuticals's net income of -$8.4M. Notably, Hansoh Pharmaceutical Group's price-to-earnings ratio is 22.72x while CASI Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansoh Pharmaceutical Group is 7.52x versus 1.94x for CASI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

China Pharma Holding has a net margin of -- compared to Hansoh Pharmaceutical Group's net margin of -101.61%. Hansoh Pharmaceutical Group's return on equity of 18.18% beat China Pharma Holding's return on equity of -66.27%.

Hansoh Pharmaceutical Group has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansoh Pharmaceutical Group has higher upside potential than China Pharma Holding, analysts believe Hansoh Pharmaceutical Group is more attractive than China Pharma Holding.

Hansoh Pharmaceutical Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.47%.

Hansoh Pharmaceutical Group has a quarterly dividend of $0.03 per share corresponding to a yield of 2.1%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansoh Pharmaceutical Group pays 19.9% of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend. Hansoh Pharmaceutical Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hansoh Pharmaceutical Group quarterly revenues are --, which are smaller than China Pharma Holding quarterly revenues of $1.1M. Hansoh Pharmaceutical Group's net income of -- is lower than China Pharma Holding's net income of -$1.1M. Notably, Hansoh Pharmaceutical Group's price-to-earnings ratio is 22.72x while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansoh Pharmaceutical Group is 7.52x versus 0.75x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -- compared to Hansoh Pharmaceutical Group's net margin of --. Hansoh Pharmaceutical Group's return on equity of 18.18% beat Sinovac Biotech's return on equity of -1.05%.

Hansoh Pharmaceutical Group has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansoh Pharmaceutical Group has higher upside potential than Sinovac Biotech, analysts believe Hansoh Pharmaceutical Group is more attractive than Sinovac Biotech.

Hansoh Pharmaceutical Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hansoh Pharmaceutical Group has a quarterly dividend of $0.03 per share corresponding to a yield of 2.1%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansoh Pharmaceutical Group pays 19.9% of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend. Hansoh Pharmaceutical Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hansoh Pharmaceutical Group quarterly revenues are --, which are smaller than Sinovac Biotech quarterly revenues of --. Hansoh Pharmaceutical Group's net income of -- is lower than Sinovac Biotech's net income of --. Notably, Hansoh Pharmaceutical Group's price-to-earnings ratio is 22.72x while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansoh Pharmaceutical Group is 7.52x versus 1.50x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -- compared to Hansoh Pharmaceutical Group's net margin of -40.75%. Hansoh Pharmaceutical Group's return on equity of 18.18% beat Zai Lab's return on equity of -35.53%.

Hansoh Pharmaceutical Group has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab has an analysts' consensus of -- which suggests that it could grow by 106.19%. Given that Zai Lab has higher upside potential than Hansoh Pharmaceutical Group, analysts believe Zai Lab is more attractive than Hansoh Pharmaceutical Group.

Hansoh Pharmaceutical Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.26999999999999%.

Hansoh Pharmaceutical Group has a quarterly dividend of $0.03 per share corresponding to a yield of 2.1%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansoh Pharmaceutical Group pays 19.9% of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend. Hansoh Pharmaceutical Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hansoh Pharmaceutical Group quarterly revenues are --, which are smaller than Zai Lab quarterly revenues of $102.3M. Hansoh Pharmaceutical Group's net income of -- is lower than Zai Lab's net income of -$41.7M. Notably, Hansoh Pharmaceutical Group's price-to-earnings ratio is 22.72x while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansoh Pharmaceutical Group is 7.52x versus 6.97x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.